Affimed N.V. (AFMD) Earns Hold Rating from Jefferies Group LLC
Jefferies Group LLC restated their hold rating on shares of Affimed N.V. (NASDAQ:AFMD) in a research report released on Thursday. Jefferies Group LLC currently has a $2.50 price target on the biopharmaceutical company’s stock.
Several other equities research analysts have also issued reports on AFMD. Oppenheimer Holdings, Inc. set a $10.00 price target on Affimed N.V. and gave the company a buy rating in a research report on Saturday, April 15th. Zacks Investment Research lowered Affimed N.V. from a buy rating to a hold rating in a research report on Friday, April 21st. ValuEngine raised Affimed N.V. from a strong sell rating to a sell rating in a research report on Friday, June 30th. Finally, SunTrust Banks, Inc. initiated coverage on Affimed N.V. in a research report on Thursday, July 13th. They set a buy rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Affimed N.V. has a consensus rating of Hold and an average target price of $4.80.
Shares of Affimed N.V. (AFMD) opened at 2.15 on Thursday. The firm’s 50-day moving average is $2.22 and its 200-day moving average is $2.23. The firm’s market cap is $94.47 million. Affimed N.V. has a 12-month low of $1.65 and a 12-month high of $3.25.
Affimed N.V. (NASDAQ:AFMD) last announced its earnings results on Wednesday, May 17th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.03. Affimed N.V. had a negative return on equity of 68.94% and a negative net margin of 655.80%. The company had revenue of $1.94 million for the quarter, compared to analyst estimates of $1.73 million. During the same period in the prior year, the company posted ($0.25) EPS. Affimed N.V.’s quarterly revenue was up 385.0% on a year-over-year basis. Equities analysts expect that Affimed N.V. will post ($0.92) earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Creative Planning raised its stake in shares of Affimed N.V. by 30.0% in the first quarter. Creative Planning now owns 65,000 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 15,000 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 479,007 shares in the last quarter. NEA Management Company LLC bought a new stake in shares of Affimed N.V. during the first quarter valued at $8,944,000. Wellington Management Group LLP raised its stake in shares of Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 1,274,852 shares in the last quarter. Finally, Tekla Capital Management LLC raised its stake in shares of Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock valued at $3,232,000 after buying an additional 1,111,111 shares in the last quarter. 42.41% of the stock is currently owned by institutional investors and hedge funds.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.